https://www.selleckchem.com/pr....oducts/5-cholesten-3
COS developers should consider the need for a COS to be global at protocol stage. Global COS should include equal representation from both LMICs and HICs at all stages of development. COS developers should consider the need for a COS to be global at protocol stage. Global COS should include equal representation from both LMICs and HICs at all stages of development. Timely publication of clinical trial results is central for evidence-based medicine. In this follow-up study we benchmark the performance of German univers
Like
Comment
Share
